Dynamic two-day forum in Singapore set to explor
Author: Michael
From global reach to breadth of innovation and a
Partnership aims to uncover molecular factors of
CCI president explains why Japan’s longer-term
Neurotech seeks to accelerate commercialization
First subjects dosed in first-in-human Phase 1 c
Vandria announced it has closed a second Series A financing round, bringing total funding to $30.7 million (CHF 28.3 million). According to the company, new investors Hevolution Foundation and Dolby Family Ventures joined the round, which aims to advance its lead candidate, VNA‑318, into clinical trials. The company said VNA‑318 is an oral mitophagy inducer targeting central nervous system (CNS) diseases linked to mitochondrial dysfunction. Vandria claims preclinical data support its potential to clear damaged mitochondria and restore cellular energy balance, offering a new therapeutic approach for age-related neurodegenerative disorders. According to Vandria, proceeds from the financing will fund a first-in-human clinical…
DeepLife secures $10m to advance AI platform des
Vancouver-based health technology company Prenuvo
Research links hidden visceral fat to abnormal p